In a recent guest blog in Nature biotechnology’s Bioentrepreneur Trade Secrets, Markus Schmidt reported about the latest developments in designing novel vaccines. The reprogramming of Mycoplasma bacteria from pathogens to vaccines is only made possible thanks to an international collaboration of synthetic biologists, systems biologists, bioinformaticians, animal health experts, biosafety specialist and ethicists within the EC H2020 project MycoSynVac.
Read the full blog here.
